|
Synonyms: APN-311 | Ch14.18 | MAb-14.18 | Unituxin®
dinutuximab is an approved drug (FDA (2015))
Compound class:
Antibody
Comment: Dinutuximab is a chimeric mouse/human monoclonal antibody targeting ganglioside-GD2.
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record. A patent search identifies US20140170155 [4] as the applicable patent. US20140170155 reveals APN311 as a formulation of the mouse-human chimeric anti-GD2 antibody ch14.18 recombinantly produced in Chinese hamster ovary (CHO) cells. Efficacy of the preferred antibody was determined by its cytolysis capacity in GD2-expressing cells, as determined by a complement dependent cytolysis assay. |
| References |
|
1. Ahmed M, Cheung NK. (2014)
Engineering anti-GD2 monoclonal antibodies for cancer immunotherapy. FEBS Lett, 588 (2): 288-97. [PMID:24295643] |
|
2. Berois N, Osinaga E. (2014)
Glycobiology of neuroblastoma: impact on tumor behavior, prognosis, and therapeutic strategies. Front Oncol, 4: 114. [PMID:24904828] |
|
3. Ladenstein R, Weixler S, Baykan B, Bleeke M, Kunert R, Katinger D, Pribill I, Glander P, Bauer S, Pistoia V et al.. (2013)
Ch14.18 antibody produced in CHO cells in relapsed or refractory Stage 4 neuroblastoma patients: a SIOPEN Phase 1 study. MAbs, 5 (5): 801-9. [PMID:23924804] |
|
4. Loibner H, Mutschlechner O, Ladenstein R, Klier I. (2014)
Method for Treating a GD2 Positive Cancer. Patent number: US20140170155. Assignee: Apeiron Biologics Ag. Priority date: 18/06/2012. Publication date: 19/06/2014. |
|
5. Mujoo K, Cheresh DA, Yang HM, Reisfeld RA. (1987)
Disialoganglioside GD2 on human neuroblastoma cells: target antigen for monoclonal antibody-mediated cytolysis and suppression of tumor growth. Cancer Res, 47 (4): 1098-104. [PMID:3100030] |
|
6. Soman G, Kallarakal AT, Michiel D, Yang X, Saptharish N, Jiang H, Giardina S, Gilly J, Mitra G. (2012)
Analytical characterization of ch14.18: a mouse-human chimeric disialoganglioside-specific therapeutic antibody. MAbs, 4 (1): 84-100. [PMID:22327432] |
